AbbVie adds to T cell engager momentum, with EvolveImmune pact starting at $65M

AbbVie, already a leader in the T cell engager field with Epkinly and a Phase 3 program, is further digging into the field with a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Novel urine-based prognostic model promises to transform bladder cancer treatment

In a study published in the journal Genes & Diseases, researchers from Fudan University, have developed a novel urine-based prognostic model that promises to transform

November 21, 2023

Roivant strikes another deal, selling dermatology spinoff to Organon in deal worth $1.2 billion

Roivant Sciences continues its dealmaking hot streak, announcing Wednesday that it would sell one of its subsidiaries to pharma company Organon in a deal worth

September 18, 2024

The Case Against White Coats; Addicted to Nasal Spray? Get Ready for a Shift With Me

The following contains links to social media websites including X, TikTok, Instagram, Facebook, and LinkedIn. “Just because I don’t wear a white coat doesn’t make

October 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.